Toronto Stock Exchange Symbol: MS
EDMONTON, April 30 /CNW/ - BioMS Medical Corp. (TSX: MS), today announced that the University of Alberta, a major shareholder of the Company, has sold 12,915,365 BioMS Medical shares.
Certain employees, officers and directors of BioMS Medical acquired 7,245,000 of the shares sold by the University of Alberta.
"We are very pleased that many of our senior management and Board members saw this as an opportunity to purchase these shares, recognizing the long-term prospects for the Company," said Kevin Giese, President and CEO of BioMS Medical. "We also thank the University of Alberta for their support over the past 10 years and continued involvement as a shareholder."
University of Alberta Vice President (Finance) Phyllis Clark added: "We have enjoyed a long and collaborative relationship with BioMS which we look forward to continuing in the future. The proceeds from the sale will be used to support the endowment fund and the teaching and research mission of the university."
About BioMS Medical Corp.
BioMS Medical is a biotechnology company engaged in the investment, development and commercialization of pharmaceutical technologies. For further information please visit our website at http://www.biomsmedical.com
This press release may contain forward-looking statements, which reflect the Corporation's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation's ongoing quarterly and annual reporting. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Medwell Capital Corp.
For further information: For further information: Tony Hesby, Ryan Giese, BioMS Medical Corp., (780) 413-7152, (780) 408-3040 Fax, E-mail: firstname.lastname@example.org, Internet: http://www.biomsmedical.com; James Smith, Investor Relations, (416) 815-0700 ext. 229, (416) 815-0080 Fax, E-mail: email@example.com